Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Correction: A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer.

Liu S, Kumari S, Hu Q, Senapati D, Venkadakrishnan VB, Wang D, DePriest AD, Schlanger SE, Ben-Salem S, Valenzuela MM, Willard B, Mudambi S, Swetzig WM, Das GM, Shourideh M, Koochekpour S, Falzarano SM, Magi-Galluzzi C, Yadav N, Chen X, Lao C, Wang J, Billaud JN, Heemers HV.

Elife. 2017 Nov 22;6. pii: e33738. doi: 10.7554/eLife.33738. No abstract available.

2.

A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer.

Liu S, Kumari S, Hu Q, Senapati D, Venkadakrishnan VB, Wang D, DePriest AD, Schlanger SE, Ben-Salem S, Valenzuela MM, Willard B, Mudambi S, Swetzig WM, Das GM, Shourideh M, Koochekpour S, Falzarano SM, Magi-Galluzzi C, Yadav N, Chen X, Lao C, Wang J, Billaud JN, Heemers HV.

Elife. 2017 Aug 18;6. pii: e28482. doi: 10.7554/eLife.28482. Erratum in: Elife. 2017 Nov 22;6:.

3.

GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.

Shourideh M, Azabdaftari G, Attwood K, DePriest A, Wadosky KM, Gillard BM, Karasik E, Heemers H, Kyprianou N, Gelman IH, Corey E, Vessella RL, Mohler JL, Koochekpour S.

Clin Cancer Res. 2016 Jul 25. pii: clincanres.0137.2016. doi: 10.1158/1078-0432.CCR-16-0137. [Epub ahead of print] Retraction in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3973.

PMID:
27458247
4.

Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.

Wei L, Wang J, Lampert E, Schlanger S, DePriest AD, Hu Q, Gomez EC, Murakam M, Glenn ST, Conroy J, Morrison C, Azabdaftari G, Mohler JL, Liu S, Heemers HV.

Eur Urol. 2017 Feb;71(2):183-192. doi: 10.1016/j.eururo.2016.07.008. Epub 2016 Jul 21.

5.

Prescription Opioids. V. Metabolism and Excretion of Oxymorphone in Urine Following Controlled Single Dose Administration.

DePriest AZ, Heltsley R, Black DL, Mitchell JM, LoDico C, Flegel R, Cone EJ.

J Anal Toxicol. 2016 Oct;40(8):566-574. Epub 2016 Jul 11.

PMID:
27405370
6.

Prescription Opioids. VI. Metabolism and Excretion of Hydromorphone in Urine Following Controlled Single-Dose Administration.

DePriest AZ, Heltsley R, Black DL, Mitchell JM, LoDico C, Flegel R, Cone EJ.

J Anal Toxicol. 2016 Oct;40(8):575-582. Epub 2016 Jul 11.

PMID:
27405368
7.

Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.

Shourideh M, DePriest A, Mohler JL, Wilson EM, Koochekpour S.

Prostate. 2016 Sep;76(12):1067-77. doi: 10.1002/pros.23190. Epub 2016 Jun 8.

PMID:
27271795
8.

Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action.

DePriest AD, Fiandalo MV, Schlanger S, Heemers F, Mohler JL, Liu S, Heemers HV.

Database (Oxford). 2016 Feb 13;2016. pii: bav125. doi: 10.1093/database/bav125. Print 2016.

9.

Metabolism and Disposition of Prescription Opioids: A Review.

DePriest AZ, Puet BL, Holt AC, Roberts A, Cone EJ.

Forensic Sci Rev. 2015 Jul;27(2):115-45. Review.

PMID:
26227254
10.

Tryptophan Scanning Reveals Dense Packing of Connexin Transmembrane Domains in Gap Junction Channels Composed of Connexin32.

Brennan MJ, Karcz J, Vaughn NR, Woolwine-Cunningham Y, DePriest AD, Escalona Y, Perez-Acle T, Skerrett IM.

J Biol Chem. 2015 Jul 10;290(28):17074-84. doi: 10.1074/jbc.M115.650747. Epub 2015 May 12.

11.

Prescription Opioids. IV: Disposition of Hydrocodone in Oral Fluid and Blood Following Single-Dose Administration.

Cone EJ, DePriest AZ, Heltsley R, Black DL, Mitchell JM, LoDico C, Flegel R.

J Anal Toxicol. 2015 Sep;39(7):510-8. doi: 10.1093/jat/bkv050. Epub 2015 May 10.

PMID:
25962610
12.

Immunoassay in healthcare testing applications.

DePriest AZ, Black DL, Robert TA.

J Opioid Manag. 2015 Jan-Feb;11(1):13-25. doi: 10.5055/jom.2015.0248. Review.

PMID:
25750161
13.

Prescription opioids. III. Disposition of oxycodone in oral fluid and blood following controlled single-dose administration.

Cone EJ, DePriest AZ, Heltsley R, Black DL, Mitchell JM, LoDico C, Flegel R.

J Anal Toxicol. 2015 Apr;39(3):192-202. doi: 10.1093/jat/bku176. Epub 2015 Jan 13.

PMID:
25589778
14.

Risks and responsibilities in prescribing opioids for chronic noncancer pain, part 2: best practices.

Cone EJ, DePriest AZ, Gordon A, Passik SD.

Postgrad Med. 2014 Nov;126(7):129-38. doi: 10.3810/pgm.2014.11.2841.

PMID:
25387221
15.

Prescribing opioids for chronic noncancer pain in primary care: risk assessment.

Gordon A, Cone EJ, DePriest AZ, Axford-Gatley RA, Passik SD.

Postgrad Med. 2014 Sep;126(5):159-66. doi: 10.3810/pgm.2014.09.2810. Review.

PMID:
25295660
16.

Determining zolpidem compliance: urinary metabolite detection and prevalence in chronic pain patients.

Schwope DM, DePriest A, Black DL, Caplan YH, Cone EJ, Heltsley R.

J Anal Toxicol. 2014 Oct;38(8):513-8. doi: 10.1093/jat/bku068.

PMID:
25217539
17.

Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence.

DePriest AZ, Miller K.

Pain Ther. 2014 Jun;3(1):1-15. doi: 10.1007/s40122-014-0026-2. Epub 2014 May 6.

18.

Uncertainty in assessing impact of drug-drug interactions on oxycodone metabolite patterns.

DePriest AZ, Puet BL, Heltsley R, Robert T, Black DL.

J Anal Toxicol. 2014 Sep;38(7):462. doi: 10.1093/jat/bku071. Epub 2014 Jul 1. No abstract available.

PMID:
24986837
19.

Prevalence of heroin markers in urine for pain management patients.

Knight J, Puet BL, DePriest A, Heltsley R, Hild C, Black DL, Robert T, Caplan YH, Cone EJ.

Forensic Sci Int. 2014 Oct;243:79-83. doi: 10.1016/j.forsciint.2014.04.037. Epub 2014 May 9.

PMID:
24858136
20.

Analysis of trafficking, stability and function of human connexin 26 gap junction channels with deafness-causing mutations in the fourth transmembrane helix.

Ambrosi C, Walker AE, Depriest AD, Cone AC, Lu C, Badger J, Skerrett IM, Sosinsky GE.

PLoS One. 2013 Aug 15;8(8):e70916. doi: 10.1371/journal.pone.0070916. eCollection 2013.

21.

Urine drug testing of chronic pain patients. V. Prevalence of propoxyphene following its withdrawal from the United States market.

Puet B, DePriest A, Knight J, Heltsley R, Black DL, Caplan YH, Cone EJ.

J Anal Toxicol. 2013 Jan-Feb;37(1):1-4. doi: 10.1093/jat/bks083. Epub 2012 Nov 5. Review.

PMID:
23129731
22.

Pseudoephedrine and false-positive immunoassay urine drug tests for amphetamine.

DePriest AZ, Knight JL, Doering PL, Black DL.

Pharmacotherapy. 2013 May;33(5):e88-9. doi: 10.1002/phar.1216. Epub 2012 Oct 12. No abstract available.

PMID:
23065913
23.

Prevalence of synthetic cannabinoids in U.S. athletes: initial findings.

Heltsley R, Shelby MK, Crouch DJ, Black DL, Robert TA, Marshall L, Bender CL, DePriest AZ, Colello MA.

J Anal Toxicol. 2012 Oct;36(8):588-93. doi: 10.1093/jat/bks066. Epub 2012 Aug 7.

PMID:
22872465
24.

Oral fluid drug testing of chronic pain patients. II. Comparison of paired oral fluid and urine specimens.

Heltsley R, Depriest A, Black DL, Crouch DJ, Robert T, Marshall L, Meadors VM, Caplan YH, Cone EJ.

J Anal Toxicol. 2012 Mar;36(2):75-80. doi: 10.1093/jat/bkr019.

PMID:
22337775
25.

Tryptophan scanning mutagenesis of the first transmembrane domain of the innexin Shaking-B(Lethal).

Depriest A, Phelan P, Martha Skerrett I.

Biophys J. 2011 Nov 16;101(10):2408-16. doi: 10.1016/j.bpj.2011.10.004. Epub 2011 Nov 15.

26.

Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs.

Heltsley R, DePriest A, Black DL, Robert T, Marshall L, Meadors VM, Caplan YH, Cone EJ.

J Anal Toxicol. 2011 Oct;35(8):529-40.

PMID:
22004671
27.

Urine drug testing of chronic pain patients. IV. prevalence of gabapentin and pregabalin.

Heltsley R, Depriest A, Black DL, Robert T, Caplan YH, Cone EJ.

J Anal Toxicol. 2011 Jul;35(6):357-9.

PMID:
21740692
28.

Urine drug testing of chronic pain patients. III. Normetabolites as biomarkers of synthetic opioid use.

Depriest A, Heltsley R, Black DL, Cawthon B, Robert T, Moser F, Caplan YH, Cone EJ.

J Anal Toxicol. 2010 Oct;34(8):444-9.

PMID:
21819788

Supplemental Content

Loading ...
Support Center